Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Sells 9,102 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 9,102 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the sale, the chief executive officer now directly owns 115,920 shares in the company, valued at approximately $5,589,662.40. This represents a 7.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Christopher Peetz also recently made the following trade(s):

• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $320,678.98.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $52.28 on Thursday. The stock has a market cap of $2.51 billion, a P/E ratio of -25.88 and a beta of 0.96. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $53.49. The company’s 50-day simple moving average is $44.49 and its 200 day simple moving average is $42.10.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. During the same period in the prior year, the firm posted ($0.57) EPS. Mirum Pharmaceuticals’s quarterly revenue was up 89.4% compared to the same quarter last year. As a group, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Leerink Partners increased their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. HC Wainwright restated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Citigroup increased their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $57.10.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares during the last quarter. Legato Capital Management LLC grew its stake in Mirum Pharmaceuticals by 7.9% during the fourth quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock worth $554,000 after buying an additional 977 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Mirum Pharmaceuticals by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock worth $421,000 after buying an additional 1,003 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Mirum Pharmaceuticals by 2.4% in the 4th quarter. Rhumbline Advisers now owns 53,113 shares of the company’s stock worth $2,196,000 after acquiring an additional 1,236 shares in the last quarter. Finally, R Squared Ltd acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $69,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.